• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Orchid Pharma receives EIR from US FDA for Tamil Nadu plant

financialexpressApril 19, 2017

Tag: Orchid Pharma , FDA

Orchid Pharma said the US health regulator has issued establishment inspection report (EIR) for its manufacturing facility in Tamil Nadu.

The company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) based on the successful inspection of the formulation manufacturing facility at Irungattukottai, Orchid Pharma said in a filing to BSE.

"The facility was inspected by the USFDA in December 2016," it added.

Upon completion of an inspection by FDA, an EIR is issued which details inspectional findings.

Previous:Mergermarket releases global PMB trend report

Next:Jubilant Life raises Rs 100 cr by issue of commercial papers

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Orchid Pharma receives EIR from US FDA for Tamil Nadu plant | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Thiophosphoramide (FDA)

Thiophosphoramide (FDA)
Clozapine (FDA)

Clozapine (FDA)
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
High quality Stability Chamber(FS/CFS Series:FDA)

High quality Stability Chamber(FS/CFS Series:FDA)
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)
Etoposide( FDA)

Etoposide( FDA)
Medroxyprogesterone Acetate(FDA)

Medroxyprogesterone Acetate(FDA)
Vitamine B12 (FDA)

Vitamine B12 (FDA)
Fluorfenicol( FDA)

Fluorfenicol( FDA)
Tacrolimus (FDA)

Tacrolimus (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service